Coston McIsaac & Partners’s AbbVie ABBV Stock Holding History

Coston McIsaac & Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$131K	Hold	522	–	–	0.03%	206
2026 Q1	$113K	Hold	522	–	–	0.03%	215
2025 Q4	$119K	Buy	522 +1	+0.2%	+$228	0.03%	201
2025 Q3	$120K	Buy	521 +12	+2%	+$2.44K	0.03%	202
2025 Q2	$94K	Buy	509 +1	+0.2%	+$186	0.02%	222
2025 Q1	$106K	Buy	508 +1	+0.2%	+$194	0.03%	185
2024 Q4	$90K	Hold	507	–	–	0.03%	202
2024 Q3	$100	Buy	507 +1	+0.2%	+$187	0.03%	185
2024 Q2	$86K	Buy	506 +1	+0.2%	+$166	0.03%	192
2024 Q1	$92K	Hold	505	–	–	0.03%	186
2023 Q4	$78K	Buy	505 +1	+0.2%	+$146	0.03%	202
2023 Q3	$75K	Buy	504 +1	+0.2%	+$147	0.03%	196
2023 Q2	$67K	Hold	503	–	–	0.02%	221
2023 Q1	$80K	Sell	503 -15	-3%	-$2.29K	0.03%	195
2022 Q4	$83	Buy	518 +2	+0.4%	+$307	0.03%	190
2022 Q3	$69K	Buy	516 +2	+0.4%	+$287	0.03%	177
2022 Q2	$79K	Buy	+514	New	+$78.5K	0.05%	106

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Coston McIsaac & Partners's ABBV Position: Q2 2026 in Review

Coston McIsaac & Partners held its AbbVie (ABBV) position steady in Q2 2026 at 522 shares worth $131K. The position accounts for 0.03% of the portfolio, ranked #206.

Coston McIsaac & Partners first reported a position in ABBV in Q2 2022 and has held it in 17 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Coston McIsaac & Partners held 522 shares of AbbVie worth $131K as of Q2 2026.
Coston McIsaac & Partners left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.03% of Coston McIsaac & Partners's portfolio in Q2 2026, its #206 holding.
Coston McIsaac & Partners first reported a position in AbbVie in Q2 2022 and has held it in 17 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.